← Back to Home

Ascendis’ Three Rare Disease Drugs Drive Revenue to More Than Double, but Profit Still Includes a Large One-Time Gain

Long-acting therapies are beginning to support Ascendis’ commercial business, but growth across its three products is uneven. Second-quarter results show that its hypoparathyroidism drug remains the main contributor, while the sale of a priority review voucher also significantly boosted quarterly profit.

By SURL BioNews

When rare disease drugs move from approval to actual sales, they begin to face another test: whether a commercial system can be established to supply patients consistently. Ascendis Pharma’s second-quarter 2026 results, released in August, illustrate this transition—three rare disease drugs are now contributing revenue, but growth is driven primarily by one product, and strong profit also benefited from a one-time transaction.

An analysis published by Yahoo Finance identified the three TransCon therapies as the company’s growth drivers. According to the unaudited financial statements Ascendis submitted to the U.S. Securities and Exchange Commission, second-quarter product sales revenue was approximately €315 million, more than double the approximately €154 million recorded in the same period last year. Including collaboration and other revenue, total revenue was €339 million, compared with €158 million a year earlier.

YORVIPATH, used to treat hypoparathyroidism in adults, generated approximately €252 million in quarterly sales, accounting for about 80% of product revenue. The growth hormone therapy SKYTROFA generated approximately €55.21 million, while the newly launched achondroplasia therapy YUVIWEL contributed approximately €7.58 million. Selling all three products has broadened the company’s revenue sources, but has yet to change its heavy reliance on YORVIPATH.

The shared concept behind these therapies is the use of TransCon technology to extend the duration of drug action. The three products use therapies related to parathyroid hormone, growth hormone, and C-type natriuretic peptide, respectively, to address different endocrine and growth disorders. Sharing a technology platform does not mean that indications, dosing schedules, or clinical benefits can be extrapolated from one product to another.

YUVIWEL’s regulatory status requires particular distinction. According to the company’s filings, it received accelerated approval from the U.S. Food and Drug Administration in February 2026 and became available in the United States in April to promote height growth in children aged two years and older with achondroplasia whose growth plates remain open. At the time these financial results were released, its application in the European Union remained under review, with the company expecting a decision in the fourth quarter. Its pending review in Europe must be distinguished from its approval in the United States.

Profit requires a further breakdown. The company also reported approximately €158 million in other operating income for the second quarter from the sale of a rare pediatric disease priority review voucher. This cannot be treated as drug sales that can recur each quarter. Selling, general and administrative expenses rose to €173 million in the same quarter, compared with approximately €108 million a year earlier, while research and development expenses increased from approximately €71.99 million to €75.89 million, showing that operating expenses are also rising as revenue expands.

These results demonstrate progress in commercializing rare disease drugs, rather than new evidence of efficacy. Going forward, the company’s ability to reduce its reliance on a single product, gradually have new drug sales take over as growth drivers, and sustain profitability after excluding one-time gains will better demonstrate the sustainability of this business model. Long-term benefits and safety for patients must still be assessed using clinical follow-up data for each product.

References

  1. Yahoo Finance Singapore
  2. U.S. Securities and Exchange Commission